Trials / Unknown
UnknownNCT04861389
Distal Transradial Access for Primary Percutaneous Coronary Intervention in STEMI Patients
The Comparison of Distal Transradial Access and Transradial Access for Primary Percutaneous Coronary Intervention in STEMI Patients(RESERVE Trial) A Single-center, Open, Prospective, Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 414 (estimated)
- Sponsor
- Shenzhen People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The transradial access (TRA) is currently the preferred approach for percutaneous coronary intervention (PCI). However, in patients with ACUTE ST-segment elevation myocardial infarction (STEMI) after emergency PCI, the high incidence of THE radial artery RAO limits the future choice of the radial artery for percutaneous intervention. The literature reported that distal transradial access (dTRA) significantly reduced RAO after elective PCI, but the application of dTRA in emergency PCI in STEMI has not been reported. We have completed 126 cases of dTRA undergoing emergency PCI after STEMI, which has been preliminarily confirmed to be safe and effective. A single-center, open, prospective, randomized controlled study is planned to compare the use of dTRA and TRA in emergency PCI in STEMI patients. The primary endpoint was the INCIDENCE of RAO within 24 hours after surgery. This clinical study verified that dTRA compared with TRA could reduce the RAO incidence of STEMI patients after emergency PCI. The project will explore a new artery approach to reduce RAO, and provide a basis for the selection of artery approach in STEMI emergency PCI patients.
Conditions
- Acute ST-segment Elevation Myocardial Infarction
- Radial Artery Occlusion
- Distal Radial Artery Approach
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Arterial access | Arterial access for primary percutaneous coronary intervention in STEMI patients |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2021-12-31
- Completion
- 2022-01-31
- First posted
- 2021-04-27
- Last updated
- 2021-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04861389. Inclusion in this directory is not an endorsement.